U.S. Markets close in 2 hrs 9 mins

Wired News – Biohaven Pharmaceutical Shares Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis Orally Dissolving Tablet

LONDON, UK / ACCESSWIRE / January 11, 2018 / Active-Investors.com has just released a free research report on Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN) ("Biohaven"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BHVN as the Company's latest news hit the wire. On January 09, 2018, the Company, a clinical-stage biopharmaceutical organization with a portfolio of innovative, late-stage product candidates for neurological diseases and rare disorders, reported positive results from its bioequivalence study with BHV-0223, which is an innovative sublingual formulation of Sanofi's oral drug Riluzole. The bioequivalence study is meant to assess the pharmacokinetic equivalence of BHV-0223 with Rilutek (riluzole), for the treatment of Amyotrophic Lateral Sclerosis (ALS). Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Biohaven Pharmaceutical Holding most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=BHVN

About BHV-0223

BHV-0223 is an innovative, sublingually, orally administered dissolving tablet (ODT), which uses the unique Zydis® ODT fast-dissolve technology. Biohaven is developing BHV-0223 as a potential treatment for patients with ALS. The tablet is being developed under an exclusive worldwide agreement with Catalent Inc., a global provider of drug delivery technology and development solutions for drugs, biologics, and consumer health products.

On February 25, 2016, Biohaven received a regulatory feedback from the US Food and Drug Administration (FDA), that the Section 505(b)(2) pathway was acceptable for BHV-0223 in ALS, and that there was no need of any additional efficacy or toxicology study for the submission of a new drug application (NDA) for this indication. This, coupled with the positive results of the bioequivalence study, would enable Biohaven to proceed towards completing an NDA and submitting it in the first half of 2018.

Study Objective and Results

The Bioequivalence Study has been specifically designed to establish the pharmacokinetic equivalence of sublingual BHV-0223, in comparison to the reference-listed drug Rilutek (riluzole), which is currently the standard of care treatment for patients suffering with ALS. For this study, a total of 138 healthy volunteers were administered BHV-0223 and Rilutek under fasted conditions.

The top-line results from the study show that 40mg dosage of sublingual BHV-0223 achieves results equivalent to 50mg dosage of Rilutek. In the pre-specified primary analysis, BHV-0223 achieved area-under-the-curve and peak exposures of about 90% and 113%, respectively, compared to those generated by generic Rilutek. The 90% confidence intervals were within the 80% to 125% range, which is used to define bioequivalence.

BHV-0223 Comparison with Rilutek

Although the FDA has approved Rilutek for the treatment of ALS, it gets difficult to administer conventional tablets to ALS patients as they have dysphagia or trouble in swallowing. On the other hand, when BHV-0223 is kept under the tongue, it dissolves in seconds and does not even require swallowing.

Also, Rilutek is often associated with dose-dependent effects on liver tests (transaminases), while BHV-0223 provides bioequivalent exposures with a 20% lower dose. This means, sublingual administration of 40mg BHV-0223 results in bioequivalent blood exposures to orally ingested 50mg tablets of Rilutek. Thus, due to this reduced drug exposure to the liver, BHV-0223 has a lower risk for causing liver test elevations.

An Important Development for ALS Patients

Positive results from the Bioequivalence Study are an important advancement for patients with ALS, especially for those can continue taking Rilutek despite difficulties in swallowing. Besides, the possibility of achieving an equivalent therapeutic exposure with a lower drug dose makes BHV-0223 more amenable to those patients who have concerns about liver toxicity.

Other Significant Developments for Biohaven

Apart from the current development in BHV-0223, Biohaven is also making significant progress in its oral, small molecule calcitonin gene receptor peptide (CGRP) antagonist for the treatment of migraine and glutamate modulation technology platforms for neurodegenerative diseases with high unmet need.

Stock Performance Snapshot

January 10, 2018 - At Wednesday's closing bell, Biohaven Pharmaceutical Holding's stock dropped 9.91%, ending the trading session at $27.09.

Volume traded for the day: 474.40 thousand shares, which was above the 3-month average volume of 305.94 thousand shares.

Stock performance in the last month – up 28.94%; previous six-month period – up 10.12%; and year-to-date - up 0.41%

After yesterday's close, Biohaven Pharmaceutical Holding's market cap was at $939.48 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors